Timothy H. Young

Timothy H. Young

Auto-generated profile, based on publicly available information

Timothy H. Young

The Jackson Laboratory Bar Harbor Maine USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 June 2023 in Experimental Dermatology
Verified
Journal Article
Closed access
AVAnita Y. Voigt
Anita Y. Voigt
AWAndrew Walter
Andrew Walter
TYTimothy H. Young
Timothy H. Young
JGJohn P. Graham
John P. Graham
BBBruna M. Batista Bittencourt
Bruna M. Batista Bittencourt
JOJulia Oh
Julia Oh

25 January 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
AVAnita Y. Voigt
Anita Y. Voigt
AWAndrew Walter
Andrew Walter
TYTimothy Young
Timothy Young
JGJohn P. Graham
John P. Graham
BBBruna M. Batista Bittencourt
Bruna M. Batista Bittencourt
JOJulia Oh
Julia Oh
The gut microbiome is increasingly recognized to alter cancer risk, progression, and response to treatments such as immunotherapy, especially in cutaneous melanoma. However, whether the microbiome influences immune checkpoint inhibitor (ICI) immunotherapy response to non-melanoma skin cancer has not yet been defined. As squamous cell carcinomas (SCC) are in closest proximity to the skin microbiome, we hypothesized that the skin microbiome, which regulates cutaneous immunity, might affect SCC-associated anti-PD1 immunotherapy treatment response. We used ultraviolet radiation to induce SCC in SKH1 hairless mice. We then treated the mice with broad-band antibiotics to deplete the microbiome, followed by colonization by candidate skin and gut bacteria or persistent antibiotic treatment, all in parallel with ICI treatment. We longitudinally monitored skin and gut microbiome dynamics by 16S rRNA gene sequencing, and tumor burden by periodic tumor measurements and histologic assessment. Our study revealed that antibiotics-induced abrogation of the microbiome reduced tumor burden, suggesting a functional role of the microbiome in non-melanoma skin cancer therapy response.